Outcome of Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients and BCR-ABL Positive Blast Cell Crisis of B-Lymphoid Lineage with Extramedullary Disease Receiving Inotuzumab Ozogamicin
Investigators evaluated the response to inotuzumab ozogamicin in 31 relapsed/refractory B cell acute lymphoblastic leukemia patients with extramedullary disease.